ZS Ph2/3 Dose-response Study in Japan

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 16% of the time (370 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-02-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: bloodjapanesedeviceto assessplacebo
  Phrases that lowered it: patientspatientcalciumtreatedefficacy and
• Sponsor's past trials: 1441 (raises risk) · Sponsor's track record
• Blinding: triple (raises risk) · Design
• Sponsor's past termination rate: 8.0% (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 133 (lowers risk) · Sponsor's track record
• Phase: 2/3 (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. NCT03528681 · started 2021 · scored riskier than 23% of active trials completed
• Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months NCT02163499 · started 2014 · scored riskier than 61% of active trials completed
• Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia NCT03172702 · started 2017 · scored riskier than 27% of active trials completed
• A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. NCT03303521 · started 2017 · scored riskier than 87% of active trials completed
• Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia. NCT02088073 · started 2014 · scored riskier than 78% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.